Clinical Trial Update: Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial updates the use of low-dose dasatinib (50 mg daily) as first-line treatment for newly diagnosed chronic-phase chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Myelogenous Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Hikma Pharmaceuticals LLC | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED